Medikabazaar reported a 57% revenue growth to ₹592 crore for the June quarter. The healthcare supply chain platform is now pushing toward an annual revenue goal of ₹3,000 crore by FY27, backed by plans to scale its OEM partnerships and global distribution network.
Detailed Coverage
Medikabazaar, a prominent player in India’s B2B healthcare supply chain, has reported a revenue of ₹592 crore for the June 2026 quarter, marking a 57% increase. This growth is part of the company's long-term strategy to reach a topline target of ₹3,000 crore by the end of the 2027 financial year.
Scaling Operations and Profitability Goals
Beyond top-line growth, the management has set a goal to increase its EBITDA—a measure of operating profitability—by fifteen times within the current fiscal year. To achieve this, the company is shifting from being a traditional distributor to providing an integrated commercial platform. This model is designed to support medical device and pharmaceutical manufacturers by offering them better access to both domestic hospitals and international markets.
A key part of this strategy involves building a network of over 100 strategic partnerships with Original Equipment Manufacturers (OEMs), many of which are expected to be exclusive. These agreements are intended to provide manufacturers with a ready-made commercial infrastructure, helping them bypass the complexities of traditional healthcare distribution. The company is supporting this transition with a team of over 400 sales professionals who interact directly with healthcare institutions.
Strategic Expansion and Global Reach
Medikabazaar’s expansion plan includes a stronger focus on institutional sales, with a dedicated team targeting central and state government healthcare projects. On the international front, the company is positioning itself as a partner for Indian manufacturers looking to export products to emerging markets in Africa, the Middle East, North Africa (MENA), the Commonwealth of Independent States (CIS), and Southeast Asia.
While the company is scaling up, its financial trajectory will depend on how effectively it manages the costs associated with this rapid expansion. Expanding a national sales force and establishing international trade channels often involves significant upfront money spent on operations and infrastructure. Investors will likely monitor whether the company can maintain these high growth rates while simultaneously achieving the targeted fifteenfold increase in operating profit.
Future updates from the company will be important to track, specifically regarding the actual commissioning of new OEM partnerships, the progress of its government-focused business segment, and its ability to maintain profit margins while investing in its global supply chain network.